German biotechnology company Biontech SE Conference with Pfizer Inc. From the United States will present a vaccine, effective against the Omicron-version of the coronavirus SARS-COV-2, by March next year. This is reported in a press release on the website of the American pharmaceutical company.
It was demonstrated that serum antibodies induced by a vaccine Pfizer-Biontech neutralize a new variant of coronavirus after three doses to levels comparable to levels observed for SARS-COV-2 wild-type after two doses. It is noted that at two doses, the activity of neutralizing antibodies against the oomikron option is reduced 25 times compared with the activity against the wild strain. This may not be enough to protect against COVID-19, however, scientists emphasize that vaccinated people still get protected against severe forms of the disease. These additional research data show that the booster vaccine with the current vaccine from Pfizer and Biontech increases the antibody titers of 25 times. These levels of antibodies are associated with high efficiency against coronavirus as a wild type and against causing strains.
companies have begun to develop an adapted vaccine against the Omicron option from November 25. It is expected that the drug will increase the level and duration of protection against COVID-19. The first parties will appear and will be ready for delivery after 100 days.